| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biochemistry and Biophysics |
Kyowa Hakko Kogyo, Ltd., Pharmaceutical Research Institute, Shizuoka 411-8731, Japan [A. A., Y. O., Y. Yamam., T-a. U., H. K., S. A., Y. Yamas.], and Geron Corporation, Menlo Park, California 94025 [K. P., R. P., E. W., M. P., S. L., A. C. C., C. B. H., S. G.]
Telomerase, the enzyme responsible for proliferative immortality, is expressed in essentially all cancer cells, but not in most normal human cells. Thus, specific telomerase inhibition is potentially a universal anticancer therapy with few side effects. We designed N3'
P5' thio-phosphoramidate (NPS) oligonucleotides as telomerase template antagonists and found that their ability to form stable duplexes with the telomerase RNA subunit was the key factor for antitelomerase activity. In biochemical assays 11–13-mer NPS oligonucleotides demonstrated sequence- and dose-dependent inhibition of telomerase with IC50 values <1 nM. Optimization of the sequence, length, and bioavailability resulted in the selection of a 13-mer NPS oligonucleotide, GRN163, as a drug development candidate. GRN163 inhibited telomerase in a cell-free assay at 45 ± 7 pM, and in various tumor cell lines at 
1 nM and approximately 0.3–1.0 µM in the presence and absence of carriers, respectively. GRN163 was competitive with telomeric primer binding, primarily because of hybridization to human telomerase RNA (hTR) component. Tumor cells treated with GRN163 in culture underwent telomere shortening, followed by cellular senescence or apoptosis after a period of time that generally correlated with initial telomere length. In a flank DU145 (prostate cancer) xenograft model, parenterally administered GRN163 caused suppression of tumor growth in the absence of gross toxicity. These data demonstrate that GRN163 has significant potential for additional development as an anticancer agent.
This article has been cited by other articles:
|
|
 |
|
  T. MATSUO, S. SHIMOSE, T. KUBO, J. FUJIMORI, Y. YASUNAGA, and M. OCHI Telomeres and Telomerase in Sarcomas Anticancer Res, October 1, 2009; 29(10): 3833 - 3836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hashizume, T. Ozawa, S. M. Gryaznov, A. W. Bollen, K. R. Lamborn, W. H. Frey II, and D. F. Deen New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163 Neuro-oncol, April 1, 2008; 10(2): 112 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Jackson, C.-H. Zhu, V. Paulson, L. Watkins, Z. G. Dikmen, S. M. Gryaznov, W. E. Wright, and J. W. Shay Antiadhesive Effects of GRN163L--An Oligonucleotide N3'->P5' Thio-Phosphoramidate Targeting Telomerase Cancer Res., February 1, 2007; 67(3): 1121 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Hochreiter, H. Xiao, E. M. Goldblatt, S. M. Gryaznov, K. D. Miller, S. Badve, G. W. Sledge, and B.-S. Herbert Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer. Clin. Cancer Res., May 15, 2006; 12(10): 3184 - 3192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. G. Dikmen, G. C. Gellert, S. Jackson, S. Gryaznov, R. Tressler, P. Dogan, W. E. Wright, and J. W. Shay In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor Cancer Res., September 1, 2005; 65(17): 7866 - 7873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, J. Crothers, C. M. Haqq, and E. H. Blackburn Cellular and Gene Expression Responses Involved in the Rapid Growth Inhibition of Human Cancer Cells by RNA Interference-mediated Depletion of Telomerase RNA J. Biol. Chem., June 24, 2005; 280(25): 23709 - 23717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dupont, J.-B. Latouche, C. Ma, and M. Sadelain Artificial Antigen-Presenting Cells Transduced with Telomerase Efficiently Expand Epitope-Specific, Human Leukocyte Antigen-Restricted Cytotoxic T Cells Cancer Res., June 15, 2005; 65(12): 5417 - 5427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. El-Daly, M. Kull, S. Zimmermann, M. Pantic, C. F. Waller, and U. M. Martens Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532 Blood, February 15, 2005; 105(4): 1742 - 1749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Incles, C. M. Schultes, H. Kempski, H. Koehler, L. R. Kelland, and S. Neidle A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells Mol. Cancer Ther., October 1, 2004; 3(10): 1201 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biroccio and C. Leonetti Telomerase as a new target for the treatment of hormone-refractory prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 407 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Hahn Targeting Cancer with Telomerase: Commentary re Q. Huang et al., A Novel Conditionally Replicative Adenovirus Vector Targeting Telomerase-Positive Tumor Cells. Clin. Cancer Res., 10: 1439-1445, 2004. Clin. Cancer Res., February 15, 2004; 10(4): 1203 - 1205. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Gray Strategies for Engineered Negligible Senescence Sci. Aging Knowl. Environ., November 5, 2003; 2003(44): pe30 - 30. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
